BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/26/2026 3:52:11 AM | Browse: 2 | Download: 0
 |
Received |
|
2025-11-19 07:25 |
|
Peer-Review Started |
|
2025-11-19 09:27 |
|
First Decision by Editorial Office Director |
|
2025-12-04 08:54 |
|
Return for Revision |
|
2025-12-04 08:54 |
|
Revised |
|
2025-12-17 12:50 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-12 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-12 07:24 |
|
Articles in Press |
|
2026-03-12 07:24 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-14 08:18 |
|
Publish the Manuscript Online |
|
2026-05-26 03:52 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Saikosaponin-d alleviates hepatic stellate cell activation and liver fibrosis by inhibiting the TGF-β1/Smads signaling pathway and blocking the EMT process
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jing Li, Meng-Xing Cao, Jun-Min Wang, Yi-Yuan Zheng, Ren-Ye Que and Liu-Bing Lin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82304932 |
| Traditional Chinese Medicine Research Project of Shanghai Municipal Health Commission |
2022QN051 |
|
| Corresponding Author |
Ren-Ye Que, Department of Gastroenterology, Shanghai Traditional Chinese Medicine Integrated Hospital, Shanghai University of Traditional Chinese Medicine, No. 230 Baoding Road, Shanghai 200082, China. 824492@qq.com |
| Key Words |
Saikosaponin-d; Transforming growth factor-β1/Smads; Epithelial-mesenchymal transition; Liver fibrosis; Mechanism |
| Core Tip |
Saikosaponin-d (SSd) is a promising therapeutic agent and potential antifibrotic drug. This study, through in vivo and in vitro models, demonstrates that SSd alleviates hepatic stellate cell activation and liver fibrosis progression by inhibiting the transforming growth factor-β1/Smads signaling pathway and effectively blocking the epithelial-mesenchymal transition process. The study also addresses the reversibility and safety issues of SSd, proposing solutions. These findings enrich the understanding of SSd’s antifibrotic molecular mechanisms and provide a theoretical basis for drug optimization and improvement. |
| Publish Date |
2026-05-26 03:52 |
| Citation |
Li J, Cao MX, Wang JM, Zheng YY, Que RY, Lin LB. Saikosaponin-d alleviates hepatic stellate cell activation and liver fibrosis by inhibiting the TGF-β1/Smads signaling pathway and blocking the EMT process. World J Hepatol 2026; 18(5): 116712 |
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i5/116712.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v18.i5.116712 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
